162 related articles for article (PubMed ID: 38378844)
41. Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma.
Li Z; Zhang X; Xue W; Zhang Y; Li C; Song Y; Mei M; Lu L; Wang Y; Zhou Z; Jin M; Bian Y; Zhang L; Wang X; Li L; Li X; Fu X; Sun Z; Wu J; Nan F; Chang Y; Yan J; Yu H; Feng X; Wang G; Zhang D; Fu X; Zhang Y; Young KH; Li W; Zhang M
Nat Commun; 2019 Sep; 10(1):4209. PubMed ID: 31527657
[TBL] [Abstract][Full Text] [Related]
42. Suppression of latent transforming growth factor-β (TGF-β)-binding protein 1 (LTBP1) inhibits natural killer/ T cell lymphoma progression by inactivating the TGF-β/Smad and p38
Lin R; Li X; Wu S; Qian S; Hou H; Dong M; Zhang X; Zhang M
Exp Cell Res; 2021 Oct; 407(1):112790. PubMed ID: 34418460
[TBL] [Abstract][Full Text] [Related]
43. Predictors of survival of natural killer/T-cell lymphoma, nasal type, in a non-Asian population: a single cancer centre experience.
Vásquez J; Serrano M; Lopez L; Pacheco C; Quintana S
Ecancermedicalscience; 2016; 10():688. PubMed ID: 27994644
[TBL] [Abstract][Full Text] [Related]
44. Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities.
Kim WY; Nam SJ; Kim S; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2015 Jun; 56(6):1778-86. PubMed ID: 25288491
[TBL] [Abstract][Full Text] [Related]
45. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
46. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
Yamaguchi M; Suzuki R; Miyazaki K; Amaki J; Takizawa J; Sekiguchi N; Kinoshita S; Tomita N; Wada H; Kobayashi Y; Niitsu N; Ando T; Maeda T; Saito B; Matsuoka H; Sakai R; Kubota N; Masaki Y; Kameoka Y; Asano N; Oguchi M; Katayama N
Ann Hematol; 2019 Jul; 98(7):1647-1655. PubMed ID: 31001658
[TBL] [Abstract][Full Text] [Related]
47. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
Vose J; Armitage J; Weisenburger D;
J Clin Oncol; 2008 Sep; 26(25):4124-30. PubMed ID: 18626005
[TBL] [Abstract][Full Text] [Related]
48. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.
Lai J; Xu P; Jiang X; Zhou S; Liu A
BMC Cancer; 2017 Jul; 17(1):507. PubMed ID: 28754096
[TBL] [Abstract][Full Text] [Related]
49. Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma.
Chan JY; Lim JQ; Ong CK
Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440582
[TBL] [Abstract][Full Text] [Related]
50. A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort.
Lim JQ; Huang D; Chan JY; Laurensia Y; Wong EKY; Cheah DMZ; Chia BKH; Chuang WY; Kuo MC; Su YJ; Cai QQ; Feng Y; Rao H; Feng LN; Wei PP; Chen JR; Han BW; Lin GW; Cai J; Fang Y; Tan J; Hong H; Liu Y; Zhang F; Li W; Poon MLM; Ng SB; Jeyasekharan A; Ha JCH; Khoo LP; Chin ST; Pang WL; Kee R; Cheng CL; Grigoropoulos NF; Tang T; Tao M; Farid M; Puan KJ; Xiong J; Zhao WL; Khor CC; Hwang W; Kim WS; Campo E; Tan P; Teh BT; Chng WJ; Rötzschke O; Tousseyn T; Huang HQ; Rozen S; Lim ST; Shih LY; Bei JX; Ong CK
Am J Hematol; 2022 Sep; 97(9):1159-1169. PubMed ID: 35726449
[TBL] [Abstract][Full Text] [Related]
51. Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma.
Chai Y; Qi F; Chen B; Gui L; Yang J; Qi S; Song Y; Li Y; Wei Y; Dong M
Ann Hematol; 2020 Jun; 99(6):1303-1309. PubMed ID: 32333152
[TBL] [Abstract][Full Text] [Related]
52. Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate.
Zhou Z; Chen X; Li Z; Wang X; Zhang M
Sci Rep; 2021 May; 11(1):11220. PubMed ID: 34045609
[TBL] [Abstract][Full Text] [Related]
53. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma.
Xiong J; Cui BW; Wang N; Dai YT; Zhang H; Wang CF; Zhong HJ; Cheng S; Ou-Yang BS; Hu Y; Zhang X; Xu B; Qian WB; Tao R; Yan F; Hu JD; Hou M; Ma XJ; Wang X; Liu YH; Zhu ZM; Huang XB; Liu L; Wu CY; Huang L; Shen YF; Huang RB; Xu JY; Wang C; Wu DP; Yu L; Li JF; Xu PP; Wang L; Huang JY; Chen SJ; Zhao WL
Cancer Cell; 2020 Mar; 37(3):403-419.e6. PubMed ID: 32183952
[TBL] [Abstract][Full Text] [Related]
54. Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review.
Yan Z; Yao S; Liu Y; Zhang J; Li P; Wang H; Chu J; Zhao S; Yao Z
Front Oncol; 2020; 10():608304. PubMed ID: 33363038
[TBL] [Abstract][Full Text] [Related]
55. Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime.
Zhang C; Xu H; Sui X; Chen L; Chen B; Lv H; Wang S; Wang X
Mol Ther Oncolytics; 2022 Jun; 25():288-304. PubMed ID: 35663228
[TBL] [Abstract][Full Text] [Related]
56. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma.
Kim WY; Jeon YK; Kim TM; Kim JE; Kim YA; Lee SH; Kim DW; Heo DS; Kim CW
Ann Oncol; 2009 Oct; 20(10):1688-96. PubMed ID: 19542249
[TBL] [Abstract][Full Text] [Related]
57. Advances and challenges of immunotherapies in NK/T cell lymphomas.
He L; Chen N; Dai L; Peng X
iScience; 2023 Nov; 26(11):108192. PubMed ID: 38026157
[TBL] [Abstract][Full Text] [Related]
58. c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma.
Zhu L; Zhang X; Fu X; Li Z; Sun Z; Wu J; Wang X; Wang F; Li X; Niu S; Ding M; Yang Z; Yang W; Yin M; Zhang L; Zhang M
J Cell Biochem; 2019 Aug; 120(8):12628-12637. PubMed ID: 30825244
[TBL] [Abstract][Full Text] [Related]
59. Resveratrol activates DNA damage response through inhibition of polo-like kinase 1 (PLK1) in natural killer/T cell lymphoma.
Sui X; Zhang C; Jiang Y; Zhou J; Xu C; Tang F; Chen B; Xu H; Wang S; Wang X
Ann Transl Med; 2020 Jun; 8(11):688. PubMed ID: 32617308
[TBL] [Abstract][Full Text] [Related]
60. Novel target and treatment agents for natural killer/T-cell lymphoma.
Tian XP; Cao Y; Cai J; Zhang YC; Zou QH; Wang JN; Fang Y; Wang JH; Guo SB; Cai QQ
J Hematol Oncol; 2023 Jul; 16(1):78. PubMed ID: 37480137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
